Merck KGaA (OTCMKTS:MKGAF – Get Free Report) saw a significant decrease in short interest in July. As of July 15th, there was short interest totalling 432,200 shares, a decrease of 16.2% from the June 30th total of 515,600 shares. Based on an average daily volume of 400 shares, the short-interest ratio is currently 1,080.5 days.
Merck KGaA Stock Performance
Shares of Merck KGaA stock opened at $180.70 on Tuesday. Merck KGaA has a 12 month low of $143.46 and a 12 month high of $193.63. The company has a quick ratio of 0.82, a current ratio of 1.29 and a debt-to-equity ratio of 0.28. The stock has a market cap of $23.35 billion, a PE ratio of 22.21 and a beta of 0.96. The business has a fifty day simple moving average of $174.18 and a 200-day simple moving average of $169.48.
Merck KGaA (OTCMKTS:MKGAF – Get Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The company reported $1.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.92 by ($0.18). Merck KGaA had a return on equity of 11.61% and a net margin of 13.09%. The business had revenue of $5.56 billion during the quarter. On average, sell-side analysts anticipate that Merck KGaA will post 9.5 EPS for the current fiscal year.
Merck KGaA Company Profile
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Featured Stories
- Five stocks we like better than Merck KGaA
- What Do S&P 500 Stocks Tell Investors About the Market?
- Why This Manufacturer is Committing to a Massive Buyback Program
- Do ETFs Pay Dividends? What You Need to Know
- Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
- Most Volatile Stocks, What Investors Need to Know
- Healthcare Stock Rides the Acute Services Phenomenon to New Highs
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.